Home LiteratureArticle Details
PMID: 280147 Published · ppublish English Comparative Study Journal Article

Relative potencies of anti-herpes compounds.

Annals of the New York Academy of Sciences ·Vol. 284 ·1977-03-04 ·Pages 49-59

Collins P, Bauer DJ

Abstract

Assessment of the relative potencies of compounds that inhibit the multiplication of herpesvirus is rendered difficult by the fact that they have been investigated by different workers who were not using comparable test systems. The relative and absolute potencies of idoxuridine, cytarabine, vidarabine, trifluorothymidine, and ara-DAP have therefore been evaluated by plaque inhibition, plaque reduction, and yield reduction tests, the most satisfactory dose-response lines being obtained by plaque reduction. The results obtained for five strains of type 1 and five of type 2 herpesvirus indicated that cytarabine was the most active compound, followed by idoxuridine and trifluorothymidine; vidarabine and ara-DAP were found to be the least active compounds. From comparisons of ED50 values derived from the dose-response lines it was found that the greater sensitivity of type 1 strains reported in the literature could only be confirmed with idoxuridine, since considerable overlaps in type sensitivity were observed with the other compounds.

MeSH Terms
Antiviral Agents/pharmacology Herpesviridae/drug effects Microbial Sensitivity Tests Viral Plaque Assay/methods Virus Cultivation
Chemicals
Antiviral Agents
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Collins P
Bauer D J
Article Info
Journal
Annals of the New York Academy of Sciences
Abbr.
Ann N Y Acad Sci
ISSN
0077-8923
Published
1977-03-04
Pages
49-59
Language
English
Region
United States
NLM ID
7506858
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com